EGFR selective tyrosine kinase inhibitors (TKIs) such as gefitinib (Iressa) and erlotinib (Tarceva) that bind to the adenosine triphosphate (ATP)-binding site of the enzyme have been used as successful treatments for NSCLC patients, particularly in the presence of activating mutations within the EGFR gene [4], [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.